Open AccessClinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma
Author(s) -
Hua Zhong,
Lan Xu,
JianJiang Zhong,
Fei Xiao,
Qiang Liu,
Honghui Huang,
Fangyuan Chen
Publication year - 2012
Publication title -
experimental and therapeutic medicine
Language(s) - English
Resource type - Journals
eISSN - 1792-1015
pISSN - 1792-0981
DOI - 10.3892/etm.2012.502
Subject(s) - diffuse large b cell lymphoma , oncogene , microrna , international prognostic index , molecular medicine , mir 155 , oncology , lactate dehydrogenase , medicine , lymphoma , carcinogenesis , chemotherapy , cell cycle , cancer research , biology , pathology , cancer , gene , biochemistry , enzyme
It has been found that aberrant expression of microRNAs (miRNAs) is strongly associated with carcinogenesis. In the present study, we investigated the expression of miR-155 and miR-146a in diffuse large B-cell lymphoma (DLBCL) patients (n=90). The expression levels of miR-155 and miR-146a were significantly higher in de novo DLBCL patients. miR-146a expression levels were associated with miR-155, lactate dehydrogenase, β 2 microglobulin, c-myc, International Prognostic Index status and Eastern Cooperative Oncology Group performance status. We found that patients with low miR-155 and miR-146a expression levels achieved a higher complete remission rate, higher overall response rate and longer progression-free survival time. Moreover, a high expression level of miR-155, but not miR-146a, was an independent indicator for chemotherapy protocol selection in our study. Patients with high expression of miR-155 received more survival benefits from rituximab treatment. These data suggest that miR-155 and miR-146a have potential as diagnostic and prognostic markers in DLBCL.